OR WAIT 15 SECS
May 17, 2016.
On May 16, 2016 Pfizer announced its plans to acquire Anacor Pharmaceuticals, a biopharmaceutical company developing small-molecule therapeutics. Under the terms of the agreement, Pfizer will acquire Anacor for $99.25 per Anacor share, for a total transaction value of approximately $5.2 billion, Pfizer said in a press announcement.
Pfizer expects to complete the acquisition in the third-quarter of 2016. The transaction will include Anacor’s flagship asset crisaborole, a differentiated non-steroidal topical PDE4 inhibitor with anti-inflammatory properties. Crisaborole is currently under review by FDA for the treatment of mild-to-moderate eczema (atopic dermatitis). In a press announcement Pfizer said that if approved, it believes peak year sales for crisborole have the potential to reach or exceed $2 billion.
Albert Bourla, group president of Pfizer’s Global Innovative Pharma and Global Vaccines, Oncology, and Consumer Healthcare Businesses, said in a press announcement that Anacor represents “an attractive opportunity” for the company. “Aancor will be a strong fit with Pfizer’s innovative business, further supporting our strategic focus on inflammation and immunology,” said Boula.
Pfizer also made headlines in late April 2016 when it launched Pfizer CentreOne, a global CMO, formed through the combination of Pfizer CentreSource and Hospira One 2 One. Pfizer acquired Hospira One 2 One in February 2015 for nearly $17 billion after the assumption of debt.